Equities Analysts Set Expectations for TSHA FY2025 Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Taysha Gene Therapies in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings per share of ($0.40) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 target price on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share.

A number of other research analysts have also recently commented on the stock. Canaccord Genuity Group boosted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, November 14th. JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Monday, January 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Price Performance

Shares of NASDAQ TSHA opened at $1.53 on Wednesday. The business has a 50-day moving average of $2.13 and a 200-day moving average of $2.10. The company has a market capitalization of $313.56 million, a price-to-earnings ratio of 2.43 and a beta of 0.95. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TSHA. Creative Planning bought a new stake in shares of Taysha Gene Therapies during the third quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. boosted its position in Taysha Gene Therapies by 79.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after acquiring an additional 17,446 shares during the period. Intech Investment Management LLC bought a new position in shares of Taysha Gene Therapies in the third quarter worth $85,000. Scientech Research LLC acquired a new position in shares of Taysha Gene Therapies during the second quarter valued at $97,000. Finally, SG Americas Securities LLC bought a new stake in shares of Taysha Gene Therapies during the third quarter valued at about $129,000. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.